Article Text

Download PDFPDF
Case report
Multimodality therapy of endometrial glassy cell carcinoma: a rare type of cancer
  1. Vera Kazakova1,
  2. Yenny Alejandra Moreno Vanegas1,
  3. Arun Kadamkulam Syriac2 and
  4. Olga Kozyreva2
  1. 1Department of Medicine, St Elizabeth's Medical Center, Boston, Massachusetts, USA
  2. 2Department of Hematology Oncology, Dana Farber Cancer Institute, St Elizabeth's Medical Center, Boston, Massachusetts, USA
  1. Correspondence to Dr Vera Kazakova; vera.kazakova{at}


Glassy cell carcinoma (GCC) is a rare histologically aggressive cancer subtype of the cervix that is associated with poor prognosis. Only 16 cases of endometrial GCC (EGCC) have been described in the literature to date. The data on prognostic factors and management of EGCC are limited and no optimal treatment protocol has been established. We describe a case of a 67-year-old woman who presented with postmenopausal bleeding and was diagnosed with stage IA EGCC. The patient’s risk factors included histology, age and lower uterine segment involvement. The patient was successfully treated with total hysterectomy and bilateral salpingo-oophorectomy with pelvic node dissection followed by adjuvant sandwich chemotherapy and radiotherapy. The patient has no evidence of disease recurrence for 18 months. This is the first case of EGCC management with adjuvant multimodality therapy.

  • cancer intervention
  • gynecological cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors VK collected the patient data and wrote the initial draft of the manuscript. VK and YAMV reviewed literature and wrote the discussion section. YAMV, AKS and OK revised and corrected the case report. All authors reviewed the final version of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.